Transfusion-associated TT virus infection and its relationship to liver disease

被引:98
作者
Matsumoto, A
Yeo, AET
Shih, JWK
Tanaka, E
Kiyosawa, K
Alter, HJ
机构
[1] Ctr Clin, Dept Transfus Med, NIH, Bethesda, MD 20892 USA
[2] Shinshu Univ, Sch Med, Dept Internal Med 2, Matsumoto, Nagano 390, Japan
关键词
D O I
10.1002/hep.510300118
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
TT virus (TTV) has been proposed as the causative agent of non-A to E hepatitis, We studied the association between TTV viremia and biochemical evidence of hepatitis in blood donors and prospectively-followed patients. TTV was found in 7.5% of 402 donors and in 11.0% of 347 patients before transfusion. The rate of new TTV infections was 4.7% in 127 nontransfused, and 26.4% in 182 transfused patients (P < .0001), The risk of infection increased with the number of units transfused (P < .0001), The rate of new TTV infections in 13 patients with non-A to E hepatitis (23.2%) was almost identical to the rate in 124 patients who were transfused, but did not develop hepatitis (21.8%). Of 45 patients with acute hepatitis C, 40.0% were simultaneously infected with TTV, TTV did not worsen the biochemical severity (mean ALT: 537 in TTV+; 550 in TTV-) or persistence of hepatitis C. In non-A to E cases, the mean ALT was 182 in those TTV-positive and 302 in TTV-negatives. No consistent relationship between alanine transaminase level and TTV DNA level was observed in 4 patients with long-term, sequential samples. Of 21 viremic subjects, 67% cleared TTV within 5 years (38% in 1 year); 33% were viremic throughout follow-up extending to 22 years. We conclude that TTV is a very common, often persistent infection that is transmitted by transfusion and by undefined nosocomial routes. We found no association between TTV and non-A to E hepatitis and no effect of TTV on the severity or duration of coexistent hepatitis C, TTV may not be a primary hepatitis virus.
引用
收藏
页码:283 / 288
页数:6
相关论文
共 25 条
[2]   EVALUATION OF BRANCHED DNA SIGNAL AMPLIFICATION FOR THE DETECTION OF HEPATITIS-C VIRUS-RNA [J].
ALTER, HJ ;
SANCHEZPESCADOR, R ;
URDEA, MS ;
WILBER, JC ;
LAGIER, RJ ;
DIBISCEGLIE, AM ;
SHIH, JW ;
NEUWALD, PD .
JOURNAL OF VIRAL HEPATITIS, 1995, 2 (03) :121-132
[3]   The incidence of transfusion-associated hepatitis G virus infection and its relation to liver disease [J].
Alter, HJ ;
Nakatsuji, Y ;
Melpolder, J ;
Wages, J ;
Wesley, R ;
Shih, JWK ;
Kim, JP .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (11) :747-754
[4]  
ALTER HJ, 1989, NEW ENGL J MED, V321, P1495
[5]  
ALTER HJ, 1994, VOX SANG, V67, pS19
[6]   TT-virus infection in North American blood donors, patients with fulminant hepatic failure, and cryptogenic cirrhosis [J].
Charlton, M ;
Adjei, P ;
Poterucha, J ;
Zein, N ;
Moore, B ;
Therneau, T ;
Krom, R ;
Wiesner, R .
HEPATOLOGY, 1998, 28 (03) :839-842
[7]  
Ferraz M L, 1996, Liver Transpl Surg, V2, P60, DOI 10.1002/lt.500020110
[8]  
KODALI VP, 1994, AM J GASTROENTEROL, V89, P1836
[9]   AN ASSAY FOR CIRCULATING ANTIBODIES TO A MAJOR ETIOLOGIC VIRUS OF HUMAN NON-A, NON-B-HEPATITIS [J].
KUO, G ;
CHOO, QL ;
ALTER, HJ ;
GITNICK, GL ;
REDEKER, AG ;
PURCELL, RH ;
MIYAMURA, T ;
DIENSTAG, JL ;
ALTER, MJ ;
STEVENS, CE ;
TEGTMEIER, GE ;
BONINO, F ;
COLOMBO, M ;
LEE, WS ;
KUO, C ;
BERGER, K ;
SHUSTER, JR ;
OVERBY, LR ;
BRADLEY, DW ;
HOUGHTON, M .
SCIENCE, 1989, 244 (4902) :362-364
[10]  
LINNEN J, 1996, SCIENCE, V271, P506